

Enzymatic Therapy

NATURAL MEDICINES®

November 6, 2003

8967 03 DEC 10 P2:10

NOV 19 2003

Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 810
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Sir or Madam:

This letter is to notify you that the following product is Manufactured, Packed, and/or Distributed by Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 has a label that contains a statement provided by section 403(r)(6) of the Federal Food, Drug and Cosmetic Act. Enzymatic Therapy, Inc. wishes to take advantage of the exemption to section 201(g)(1)(C) of the act and comply with section 403(r)(6) of the act. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

<u>PRODUCT NAME</u>	<u>STATEMENTS</u>	<u>INGREDEINT(S) TO WHICH THE CLAIM REFERS</u>
OsteoPrime®*	With just three simple steps Easy Answers Stage 3 gives you a full range of nutritional support, keeps those bones healthy and strong and controls menopausal symptoms.*	Vitamin C, Vitamin D, Vitamin K, Thiamin, Riboflavin, Niacin, Vitamin B6, Folic Acid, Vitamin B12, Pantothenic Acid, Calcium, Magnesium, Zinc, Selenium, Copper, Manganese, Chromium, Molybdenum, Sodium, Betaine HCl, Silicon, Boron, Strontium

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: _____

Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 11/6/03

825 Challenger Drive
Green Bay, WI 54311-8328
Ph: 920-469-1313
Fax: 888-570-6460
www.enzy.com

OsteoPrime 9e


975 0162

LET

13343

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,

A handwritten signature in black ink that reads "Michael P. Devereux". The signature is written in a cursive style with a large, stylized initial "M".

Michael P. Devereux
Chief Financial Officer

Enzymatic Therapy

NATURAL MEDICINES®

November 7, 2003

Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 810
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740


RE: Label Claims/Disclaimers

Dear Sir or Madam:

This letter is to notify you that the following product is Manufactured, Packed, and/or Distributed by Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 has a label that contains a statement provided by section 403(r)(6) of the Federal Food, Drug and Cosmetic Act. Enzymatic Therapy, Inc. wishes to take advantage of the exemption to section 201(g)(1)(C) of the act and comply with section 403(r)(6) of the act. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

<u>PRODUCT NAME</u>	<u>STATEMENTS</u>	<u>INGREDEINT(S) TO WHICH THE CLAIM REFERS</u>
OsteoPrime®*	With Easy Answers Stage 2 you can cover all your nutritional bases, support bone health and find relief from symptoms of perimenopause.*	Vitamin C, Vitamin D, Vitamin K, Thiamin, Riboflavin, Niacin, Vitamin B6, Folic Acid, Vitamin B12, Pantothenic Acid, Calcium, Magnesium, Zinc, Selenium, Copper, Manganese, Chromium, Molybdenum, Sodium, Betaine HCl, Silicon, Boron, Strontium

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 

Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 11/7/03

825 Challenger Drive

Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

OsteoPrime 10e

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,


Michael P. Devereux
Chief Financial Officer